Regeneron Pharmaceuticals, Inc. which can be found using ticker (REGN) now have 23 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $1,185.00 and $720.00 with the average target price sitting at $1,053.60. Given that the stocks previous close was at $955.76 this would indicate that there is a potential upside of 10.2%. The day 50 moving average is $942.14 and the 200 moving average now moves to $873.54. The company has a market cap of 106.66B. The current share price for the company is: $968.00 USD
The potential market cap would be $117,578,705,116 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 28.57, revenue per share of $122.57 and a 7.74% return on assets.
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, REGEN-COV, Kevzara (sarilumab) Solution for Subcutaneous Injection, Evkeeza (evinacumab) Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. The Company also provides Expresse service assurance and CloudCheck WiFi experience management solutions.
